A Randomized Phase II/III Trial of Tri-weekly Intravenous versus Tri-weekly Intraperitoneal Carboplatin Both in Combination with Weekly Intravenous Paclitaxel for Newly Diagnosed Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer - IntraPeritoneal therapy for Ovarian Cancer with Carboplatin Trial

Gynecologic Oncology Trial and Investigation Consortium / Japanese Gynecologic Oncology Group0 个研究点目标入组 655 人开始时间: 2010年6月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients assumed to have a borderline malignancy of the ovary, fallopian tube, or primary peritoneal cancer 2) Patients who have received previous chemotherapy or radiation therapy to treat the current disease 3) Patients who have a synchronous malignancy or who have been progression-free less than 5 years for a metachronous malignancy (Patients with basal and squamous cell carcinoma of the skin, as well as carcinoma in situ, and intramucosal carcinoma cured by local treatment, are eligible for the study) 4) Patients with serious medical complications, such as serious heart disease, cerebrovascular accidents, uncontrolled diabetes mellitus, uncontrolled hypertension, pulmonary fibrosis, interstitial pneumonitis, active bleeding, an active gastrointestinal ulcer, or a serious neurological disorder 5) Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated castor oil 6) Patients with a pleural effusion requiring continuous drainage 7) Patients with an active infection requiring antibiotics 8) Patients who are pregnant, nursing or of child-bearing potential 9) Patients with evidence upon physical examination of brain tumor and any brain metastases 10) Patients for whom completion of this study and/or follow-up is deemed inappropriate for any reason 11) Patients with any signs/symptoms of interstitial pneumonia

发起方

Gynecologic Oncology Trial and Investigation Consortium / Japanese Gynecologic Oncology Group